Day One Biopharmaceuticals, Inc. (DAWN) reported Q4 Revenue ; Offers Guidance

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) reported Q4 Revenue for the quarter came in at $52.8 million versus the consensus estimate of $45.86 million.

GUIDANCE:

Day One Biopharmaceuticals, Inc. sees FY2026 revenue of $225-250 million, versus the consensus of $236.6 million.

For earnings history and earnings-related data on Day One Biopharmaceuticals, Inc. (DAWN) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• EagleOne Metals closes $225,199 non-brokered private placement
• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report